ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Acetaminophen

Also written as “Paracetamol”, “IV Acetaminophen” and “Experimental paracetamol formulation”.

Its studies are mostly in Pain · Pain, Postoperative · Migraine Disorders · Common Cold · Fever, led by 26 companies.

Drug pageAcetaminophen: every studyMany companies study it; this page follows only the 123 they lead. All 662 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 13, 2005123 company-led studies, 1 open or runningNext primary completion: May 17, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only390 open or runningphase 4since Sep 13, 2005Sep 13, 2005none ahead
GlaxoSmithKlineits history only240 open or runningphase 4since Feb 18, 2010Jun 2, 2006none ahead
Keenova Therapeuticsits history only110 open or runningphase 4since Feb 5, 2016Nov 14, 2006none ahead
Allodynic Therapeuticsits history only60 open or runningphase 3since Jun 8, 2017Feb 17, 2017none ahead
Novartisits history only60 open or runningphase 4since Jun 19, 2007Jan 29, 2007none ahead
Sanofiits history only41 open or runningphase 3since Feb 12, 2007Feb 12, 2007May 17, 2027phase 2 · NCT06647407
Sun Pharmaceutical Industriesits history only40 open or runningno phasesince Feb 18, 2010Feb 18, 2010none ahead
AFT Pharmaceuticalsits history only30 open or runningphase 3since Aug 16, 2011Aug 16, 2011none ahead
Nevakarits history only30 open or runningphase 2since Jul 8, 2019Jul 8, 2019none ahead
Angelini Pharmaits history only20 open or runningphase 2since Apr 9, 2015Apr 9, 2015none ahead
AstraZeneca10 open or runningphase 1since Aug 24, 2018Aug 24, 2018none ahead

Also a collaborator on its studies: Nevakar Injectables, Cross, Cross Research, Premier Research Group, Aptuit, MDS Pharma Services and PriCara, Unit of Ortho-McNeil.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 24, 2018First study: phase 1 study in Neurofibromatosis 1First studyNCT03649165 · 24 enrolled · United States

TargetBeta

“Cyclooxygenase inhibitor; Anandamide amidohydrolase inhibitor; Vanilloid receptor opener”ChEMBL 37, by rule

Studies

The one study AstraZeneca leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03649165Neurofibromatosis 1 · United States1CompletedOct 21, 201824

How it is read

Names in the registry

  • “Acetaminophen”, 24 entries
  • “Paracetamol”, 10 entries
  • “IV Acetaminophen”, 10 entries
  • “Experimental paracetamol formulation”, 5 entries
  • “acetaminophen”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.